PT1147114E - Novos aralquilaminas de espirofuropiridinas uteis em terapia. - Google Patents

Novos aralquilaminas de espirofuropiridinas uteis em terapia.

Info

Publication number
PT1147114E
PT1147114E PT99967044T PT99967044T PT1147114E PT 1147114 E PT1147114 E PT 1147114E PT 99967044 T PT99967044 T PT 99967044T PT 99967044 T PT99967044 T PT 99967044T PT 1147114 E PT1147114 E PT 1147114E
Authority
PT
Portugal
Prior art keywords
spirofuropyridines
aralquilamins
uprising
therapy
new
Prior art date
Application number
PT99967044T
Other languages
English (en)
Inventor
Eifion Phillips
James Loch
George Mullen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1147114E publication Critical patent/PT1147114E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PT99967044T 1999-01-15 1999-12-23 Novos aralquilaminas de espirofuropiridinas uteis em terapia. PT1147114E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds

Publications (1)

Publication Number Publication Date
PT1147114E true PT1147114E (pt) 2003-10-31

Family

ID=20414101

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99967044T PT1147114E (pt) 1999-01-15 1999-12-23 Novos aralquilaminas de espirofuropiridinas uteis em terapia.

Country Status (34)

Country Link
US (2) US6995167B2 (pt)
EP (1) EP1147114B1 (pt)
JP (1) JP2002534525A (pt)
KR (1) KR100660496B1 (pt)
CN (1) CN1132837C (pt)
AR (1) AR022283A1 (pt)
AT (1) ATE240960T1 (pt)
AU (1) AU775433B2 (pt)
BR (1) BR9916906A (pt)
CA (1) CA2359990A1 (pt)
CZ (1) CZ20012554A3 (pt)
DE (1) DE69908185T2 (pt)
DK (1) DK1147114T3 (pt)
EE (1) EE04528B1 (pt)
ES (1) ES2200590T3 (pt)
HK (1) HK1040517B (pt)
HU (1) HUP0200513A3 (pt)
ID (1) ID30034A (pt)
IL (1) IL144266A0 (pt)
IS (1) IS6000A (pt)
MY (1) MY118109A (pt)
NO (1) NO20013478L (pt)
NZ (1) NZ512733A (pt)
PT (1) PT1147114E (pt)
RU (1) RU2233282C2 (pt)
SA (1) SA00200987B1 (pt)
SE (1) SE9900100D0 (pt)
SI (1) SI1147114T1 (pt)
SK (1) SK9932001A3 (pt)
TR (1) TR200102042T2 (pt)
TW (2) TWI227237B (pt)
UA (1) UA71598C2 (pt)
WO (1) WO2000042044A1 (pt)
ZA (1) ZA200105527B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
DK1397366T3 (da) * 2001-06-01 2007-05-07 Astrazeneca Ab Hidtil ukendt ligander for nicotinacetylcholinreceptorer egnede i terapi
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
IL160884A0 (en) * 2001-10-02 2004-08-31 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MXPA04010193A (es) * 2002-04-18 2005-02-03 Astrazeneca Ab Compuesto de tienilo.
EP1499616B1 (en) * 2002-04-18 2009-06-17 AstraZeneca AB Heterocyclic compounds
AU2003225456B2 (en) * 2002-04-18 2009-02-05 Astrazeneca Ab Furyl compounds
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
EP1949901B1 (en) * 2002-12-06 2014-02-12 The Feinstein Institute for Medical Research A method for determining a cholinergic agonist selective for an alpha 7 nicotinic receptor
WO2004063201A1 (ja) * 2003-01-08 2004-07-29 Mitsubishi Pharma Corporation 統合失調症治療剤
WO2005000250A2 (en) * 2003-06-24 2005-01-06 Johns Hopkins University Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor
CN100494202C (zh) * 2003-10-21 2009-06-03 阿斯利康(瑞典)有限公司 螺呋喃并吡啶芳基衍生物
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
EP2336128A1 (en) 2004-03-25 2011-06-22 Memory Pharmaceuticals Corporation Benzoisothiazoles and preparation and uses thereof
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
CA2741029A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP3357495B1 (en) 2008-11-19 2019-12-25 Axovant Sciences GmbH Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8445696B2 (en) * 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
CA2989633A1 (en) 2010-05-17 2011-11-24 Forum Pharmaceuticals Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
EP2838902B1 (en) 2012-04-12 2018-12-05 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての1−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE122353T1 (de) * 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
JPH0195922A (ja) 1987-10-08 1989-04-14 Mazda Motor Corp 車両のサスペンション制御装置
SK282366B6 (sk) * 1994-08-24 2002-01-07 Astra Aktiebolag Spiro-azabicyklická zlúčenina, farmaceutický prípravok s jej obsahom, spôsob prípravy, medziprodukty tohto spôsobu a jej použitie v medicíne
ES2156998T3 (es) * 1995-07-28 2001-08-01 Abbott Lab Compuestos de furopiridina, tienopiridina, pirrolopiridina y de pirimidina, piridazina y triazina relacionados utiles para controlar la transmision sinaptica quimica.
US6156783A (en) 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
DE69908185D1 (de) 2003-06-26
HK1040517A1 (en) 2002-06-14
TW200413387A (en) 2004-08-01
US6995167B2 (en) 2006-02-07
NZ512733A (en) 2003-08-29
CN1132837C (zh) 2003-12-31
SA00200987B1 (ar) 2006-11-07
NO20013478D0 (no) 2001-07-13
CN1337964A (zh) 2002-02-27
JP2002534525A (ja) 2002-10-15
IS6000A (is) 2001-07-12
RU2233282C2 (ru) 2004-07-27
TR200102042T2 (tr) 2002-05-21
SI1147114T1 (en) 2003-12-31
MY118109A (en) 2004-08-30
ID30034A (id) 2001-11-01
KR20010086167A (ko) 2001-09-08
ATE240960T1 (de) 2003-06-15
UA71598C2 (en) 2004-12-15
EP1147114B1 (en) 2003-05-21
KR100660496B1 (ko) 2006-12-22
NO20013478L (no) 2001-09-14
HUP0200513A2 (en) 2002-06-29
EE200100370A (et) 2002-10-15
HK1040517B (zh) 2003-09-05
AU775433B2 (en) 2004-07-29
DK1147114T3 (da) 2003-09-15
SE9900100D0 (sv) 1999-01-15
EP1147114A1 (en) 2001-10-24
DE69908185T2 (de) 2004-06-03
AU2334300A (en) 2000-08-01
ZA200105527B (en) 2002-10-04
BR9916906A (pt) 2001-10-30
ES2200590T3 (es) 2004-03-01
US20030149065A1 (en) 2003-08-07
EE04528B1 (et) 2005-08-15
HUP0200513A3 (en) 2004-07-28
CA2359990A1 (en) 2000-07-20
IL144266A0 (en) 2002-05-23
CZ20012554A3 (cs) 2002-01-16
AR022283A1 (es) 2002-09-04
WO2000042044A1 (en) 2000-07-20
TWI227237B (en) 2005-02-01
SK9932001A3 (en) 2002-04-04
US7196096B2 (en) 2007-03-27
US20050250802A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
PT1147114E (pt) Novos aralquilaminas de espirofuropiridinas uteis em terapia.
DK1637127T3 (da) Terapeutisk mikroskum
DE69924365D1 (de) Massagegerät
AR028622A1 (es) Derivados de tropano utiles en terapia
DE60001530D1 (de) Verbinder
DE60006630D1 (de) Verbinder
DE60020922D1 (de) Verbinder
PT1060695E (pt) Cadeira empilhavel
FI20000863A (fi) Uusi hoitomenetelmä
DE60042231D1 (de) Verbinder
DE69920862D1 (de) Verbinder
DE60008069D1 (de) Verbinder
DE60019059D1 (de) Verbinder
DE60001032D1 (de) Verbinder
DE60025681D1 (de) Verbinder
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
NO20005179D0 (no) Medikament behandling
DE60043606D1 (de) Verbinder
DE60044218D1 (de) em
DE60015473D1 (de) Verbinder
DE60027520D1 (de) Verbinder
DE60001783D1 (de) Verbinder
DE60026234D1 (de) Verbinder
NO20013337L (no) Ny behandling
DE60003993D1 (de) Verbinder